Global pharmaceutical company Pfizer (NYSE: PFE) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 5.4% year on year to $14.45 billion. On the other hand, the company’s full-year revenue guidance of $61 billion at the midpoint came in 0.6% below analysts’ estimates. Its non-GAAP profit of $0.75 per share was 3.9% above analysts’ consensus estimates.

Is now the time to buy PFE? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Pfizer’s first quarter results reflected continued momentum in its core portfolio, with management attributing growth to strong performance in recently launched and acquired products, particularly in oncology and migraine therapies. CEO Albert Bourla credited a 22% increase in revenues from new products and acquisitions, highlighting the success of the Seagen integration and robust demand for Nurtec. Management also pointed to positive developments in legal settlements, which have improved clarity on post-2028 growth and cash flow. CFO David Denton emphasized ongoing cost management and targeted R&D investments as further contributors to the quarter’s outperformance.

Looking ahead, Pfizer’s 2026 outlook is shaped by its advancing research pipeline, expansion in obesity and oncology therapies, and strategic business development. Management believes the Vyndamax patent settlement and a favorable European court decision will support a high single-digit compound annual growth rate post-2028. Bourla noted, “We intend to advance 10 Phase III obesity studies this year,” reflecting plans to expand Pfizer’s presence in weight management. The company also aims to sustain its leadership in vaccines and maintain capital allocation flexibility for R&D, acquisitions, and shareholder dividends.

Key Insights from Management’s Remarks

Management attributed revenue growth to product launches in oncology and migraine, successful integration of recent acquisitions, and progress in legal and R&D milestones.

• Oncology portfolio expansion: The integration of Seagen has strengthened Pfizer’s oncology business, with Seagen products driving 20% annual operational growth and broadening physician engagement. Management cited progress in antibody-drug conjugate (ADC) platforms as a key differentiator for future growth.
• Obesity drug pipeline: The Metsera acquisition underpins Pfizer’s entry into next-generation obesity treatments, with plans to advance 10 pivotal studies in 2026. Management highlighted differentiated, long-acting peptide candidates and a targeted first approval timeline of 2028.
• Growth in migraine therapy: Following the Biohaven acquisition, Nurtec achieved 41% operational growth due to increasing demand for both acute and preventive migraine treatments. Management sees further expansion potential within the oral CGRP class.
• Legal settlements and cash flow: Settlements related to Vyndamax patents and a favorable Belgian court ruling on EU vaccine contracts have improved Pfizer’s post-2028 revenue profile and cash flow visibility, supporting long-term capital allocation plans, including dividends.
• Strategic cost management: Total adjusted operating expenses were $5.5 billion for the first quarter, with adjusted SI&A expenses decreasing by 5% operationally and adjusted R&D expenses increasing by 11%. Management reaffirmed progress towards $7.2 billion in cost savings by the end of 2026, and the adjusted operating margin was 38% for the quarter, demonstrating effective cost management and revenue performance.

Drivers of Future Performance

Pfizer’s guidance for the year centers on pipeline advancement in obesity and oncology, execution on recent product launches, and disciplined capital management.

• Pipeline-driven revenue growth: Management expects new clinical data and product launches in oncology, obesity, and vaccines to be primary growth engines. The company is targeting pivotal study starts and regulatory milestones that could enable future revenue acceleration, particularly post-LOE (loss of exclusivity) events.
• Legal and patent milestones: The extension of Vyndamax patent protection and European legal clarity on vaccine contracts reduce near-term risks and provide a more predictable cash flow outlook. This improved visibility informs investment in R&D, business development, and potential share repurchases.
• Market access and competitive pressures: Management recognizes the need to sustain market share in core vaccine and specialty markets, while navigating evolving reimbursement environments and increasing competition from biosimilars and other innovative therapies.

Catalysts in Upcoming Quarters

Key factors to watch include (1) the pace and results of pivotal studies in obesity and oncology, (2) execution of cost savings and potential capital allocation actions following increased cash flow visibility, and (3) the impact of market dynamics on vaccine uptake and specialty drug launches. Progress in advancing the regulatory pipeline and business development activities will also be important to track.

Pfizer currently trades at $26.50, in line with $26.33 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).

Our Favorite Stocks Right Now

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.